Chromium-based itaconic acid-functionalized MOF: a microcarrier for sustained drug release, synergistic antibacterial effect with metronidazole, and enhanced infection control

Abstract

This study presents the investigation of, previously synthesized and characterized by our group, Cr-IA MOF (IA = Itaconic acid; MOF = metal-organic framework) as a drug carrier for targeted delivery and its antibacterial properties. Biocompatibility was assessed through cytotoxicity testing, while the drug loading and controlled release abilities were evaluated in vitro. Stability of the complex towards corrosion was assessed while colloidal stability was studied in water and PBS (Phosphate buffered saline) media and evaluated by DLS study. FTIR and DLS confirmed the successful encapsulation of drugs within the MOF structure. Cr-IA MOF demonstrated high drug-loading capacities, with 72.6 mg/g for ibuprofen, 21.9 mg/g for amoxicillin, and 33 mg/g for metronidazole, with sustained release over 72 h. Release studies showed near-complete release of amoxicillin, while metronidazole exhibited 82% release during the same period. Notably, the Cr-IA MOF, when loaded with metronidazole, exhibited a synergistic antibacterial effect, significantly enhancing its efficacy against pathogenic bacteria compared to the drug alone. These results underscore the potential of Cr-IA MOF as promising microcarrier for drug loading and release applications, especially in the context of controlled release and enhanced antibacterial performance. The findings emphasize the potential of Cr-IA MOF as a versatile microcarrier for controlled drug release and improved antibacterial performance, particularly with the synergistic effect observed in the combination of Cr-IA MOF and metronidazole.

Graphical abstract